A new class of 2,6-disubstituted morpholine N-arylsulfonamide gamma-secretase inhibitors was designed based on the introduction of a morpholine core in lieu or piperidine in our lead series. This resulted in compounds with improved CYP 3A4 profiles. Several analogs that were active at lowering Abeta levels in Tg CRND8 mice upon oral administration were identified.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.bmcl.2009.09.055 | DOI Listing |
Publication Analysis
Top Keywords
gamma-secretase inhibitors
8
cyp 3a4
8
novel orally
4
orally active
4
active morpholine
4
morpholine n-arylsulfonamides
4
n-arylsulfonamides gamma-secretase
4
inhibitors low
4
low cyp
4
3a4 liability
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!